T2000
Phase 2Small molecule
Sun Pharmaceutical Industries, Inc.T2000 is one of 47 small molecule programs targeting Dystonia. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
46 competitors in Essential Tremor
#DrugCompanyPhaseTrials
1Namenda
AbbVieApproved
Marinol
Alnylam PharmaceuticalsApproved
Epidiolex
Jazz PharmaceuticalsApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Topamax
WWim Janssens
Approved
Mirapex
Boehringer IngelheimPhase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Xyrem
Jazz PharmaceuticalsPhase 2
Zonegran
AAzurity Pharmaceuticals
Phase 2
Campral
FForest Laboratories
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for T2000. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details